Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigation...
June 03 2020 - 7:00AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates for immuno-inflammatory diseases, today announced the
publication of an abstract at the 2020 European Congress of
Rheumatology (EULAR 2020 E-Congress) being held June 3-6, 2020.
The abstract details are as follows:
Abstract No: SAT0143Title: A Phase 1 Study in Healthy Volunteers
Exploring the Safety, Pharmacokinetics and Pharmacodynamics of
ATI-450: A Novel Oral MK2 InhibitorAuthors: J. Schnyder, J.
Monahan, W. Smith, H. Hope, D. Kelly, D. Burt, E. Huff, A. Kaul, A.
Hildebrand, B. Burnette, N. Klug, M. Bangs, D. Gordon
The abstract is published in the electronic Abstract Archive
located here: “Abstract Archive.”
About ATI-450
ATI-450 is an investigational oral mitogen-activated protein
kinase-activated protein kinase 2 (MK2) inhibitor in Phase 2
clinical development. This mechanism leads to the inhibition of
multiple cytokines, chemokines, matrix metalloproteases and other
inflammatory signals. Key inflammatory cytokines driven by this
mechanism include tumor necrosis factor α (TNFα) and
interleukin-1α, -1β, -6 and -8 (IL1α, IL1β, IL6 and IL8). Aclaris
is developing ATI-450 as a potential treatment for rheumatoid
arthritis and other immuno-inflammatory diseases.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com and follow Aclaris on
LinkedIn or Twitter @aclaristx.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,”
and similar expressions, and are based on Aclaris' current beliefs
and expectations. These forward-looking statements include
expectations regarding the clinical development of ATI-450. These
statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such
statements. Risks and uncertainties that may cause actual results
to differ materially include uncertainties inherent in the conduct
of clinical trials, Aclaris’ reliance on third parties over which
it may not always have full control, Aclaris’ ability to enter into
strategic partnerships on commercially reasonable terms, the
uncertainty regarding the COVID-19 pandemic and other risks and
uncertainties that are described in the Risk Factors section of
Aclaris' Annual Report on Form 10-K for the year ended December 31,
2019, Aclaris’ Quarterly Report on Form 10-Q for the quarter ended
March 31, 2020, and other filings Aclaris makes with the U.S.
Securities and Exchange Commission from time to time. These
documents are available under the “SEC filings” section of the
Investors page of Aclaris’ website at http://www.aclaristx.com. Any
forward-looking statements speak only as of the date of this press
release and are based on information available to Aclaris as of the
date of this release, and Aclaris assumes no obligation to, and
does not intend to, update any forward-looking statements, whether
as a result of new information, future events or otherwise.
Aclaris
Contact:investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Sep 2023 to Sep 2024